Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2007, Article ID 39245, 6 pages
Research Article

CRALBP is a Highly Prevalent Autoantigen for Human Autoimmune Uveitis

1Institute for Animal Physiology, Ludwig-Maximilians University, Veterinärstraße 13, Munich 80539, Germany
2Cole Eye Institute and Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
3Section of Immunobiology, Department of Ophthalmology, Ludwig-Maximilians University, Mathildenstraße 8, Munich 80336, Germany
4Institute of Human Genetics, GSF National-Research Center for Environment and Health, Ingolstaedter Landstraße 1, Neuherberg 85764, Germany
5Institute of Human Genetics, Technical University of Munich, Trogerstraße 32, Munich 81675, Germany

Received 18 June 2007; Accepted 20 August 2007

Academic Editor: Eiji Matsuura

Copyright © 2007 Cornelia A. Deeg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cellular retinaldehyde binding protein (CRALBP) is an autoantigen in spontaneous equine recurrent uveitis. In order to test whether CRALBP contributes to human autoimmune uveitis, the specificity of antibodies from human uveitis patient's sera was first evaluated in two-dimensional (2D) Western blot analysis. Subsequent identification of the immunoreactive proteins by mass spectrometry resulted in the identification of CRALBP as a putative autoantigen. Additionally, sera from human uveitis and control patients were by Western blot using purified human recombinant CRALBP. Anti-CRALBP autoantibodies occur more frequently (P<.01) in human uveitis patients than in normal controls. Thirty out of 56 tested uveitis patient's sera contained autoantibodies reactive against CRALBP, compared to only four out of 23 normal control subjects. The presence of CRALBP autoantibodies in 54% of tested uveitis patients supports CRALBP as a possible autoantigen in human autoimmune uveitis.